Published in Sci Rep on March 14, 2017
Liver fibrosis. J Clin Invest (2005) 17.27
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol (2004) 6.75
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35
Liver cirrhosis. Lancet (2008) 6.11
Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27
Biological interaction between lymphocytes and other cells. Br J Haematol (1956) 4.70
The liver as an immunological organ. Hepatology (2006) 3.86
Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology (2006) 3.03
IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections. Hepatology (2015) 2.76
Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology (2006) 2.65
Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology (2012) 2.58
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Internalization of NK cells into tumor cells requires ezrin and leads to programmed cell-in-cell death. Cell Res (2009) 2.07
The cell biology of cell-in-cell structures. Nat Rev Mol Cell Biol (2008) 1.96
Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol (2006) 1.86
Attenuated liver fibrosis in the absence of B cells. J Clin Invest (2005) 1.82
STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology (2006) 1.80
Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology (2007) 1.75
NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut (2011) 1.75
Amelioration of hepatic fibrosis by NK cell activation. Gut (2010) 1.71
Macrophage heterogeneity in liver injury and fibrosis. J Hepatol (2014) 1.63
Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology (2009) 1.61
Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology (2012) 1.60
Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology (2010) 1.45
Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am J Physiol Gastrointest Liver Physiol (2007) 1.34
Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology (2008) 1.31
Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol (2008) 1.30
TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog (2012) 1.25
Accelerated liver fibrosis in hepatitis B virus transgenic mice: involvement of natural killer T cells. Hepatology (2010) 1.24
Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology (2014) 1.14
IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol (2013) 1.14
The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol (2014) 1.08
NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab Invest (2012) 1.06
Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice. Hepatology (2011) 1.05
Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis. Expert Rev Gastroenterol Hepatol (2007) 0.91
Natural killer cells are characterized by the concomitantly increased interferon-γ and cytotoxicity in acute resolved hepatitis B patients. PLoS One (2012) 0.87
Th17 cells regulate liver fibrosis by targeting multiple cell types: many birds with one stone. Gastroenterology (2012) 0.86
Natural Killer Cells and Liver Fibrosis. Front Immunol (2016) 0.84
Attenuated liver fibrosis in the absence of B cells. Hepatology (2006) 0.83
Significance of histopathological features in differentiating autoimmune liver disease from nonautoimmune chronic liver disease in children. Eur J Gastroenterol Hepatol (2013) 0.82
NKp30 isoforms in patients with chronic hepatitis C virus infection. Immunology (2015) 0.82
Exosome-mediated activation of toll-like receptor 3 in stellate cells stimulates interleukin-17 production by γδ T cells in liver fibrosis. Hepatology (2016) 0.82
Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin Rev Allergy Immunol (2015) 0.80
NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice. Hepatology (2016) 0.79
Current trends in the diagnosis and treatment of autoimmune hepatitis in Japan. Hepatol Res (2011) 0.79
Emperipolesis is a potential histological hallmark associated with chronic hepatitis B. Curr Mol Med (2015) 0.78
Suicidal emperipolesis: a process leading to cell-in-cell structures, T cell clearance and immune homeostasis. Curr Mol Med (2015) 0.78
Negative regulation of Schistosoma japonicum egg-induced liver fibrosis by natural killer cells. PLoS Negl Trop Dis (2012) 0.78
Differential characteristics and prognosis of patients with HBV-related acute-on-chronic liver failure defined by EASL-CLIF criteria. Hepatol Res (2017) 0.75
Activating Transcription Factor 3 Is a Target Molecule Linking Hepatic Steatosis to Impaired Glucose Homeostasis. J Hepatol (2017) 0.75
Current progress in host innate and adaptive immunity against hepatitis C virus infection. Hepatol Int (2017) 0.75